Advertisement
LLY vs PFE
Which Stock Would AI Choose? Eli Lilly (LLY) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- LLY shares have declined about 17% year-to-date (YTD), underperforming amid recent market pullbacks, while PFE has gained roughly 13% YTD, showing relative resilience.
- Recent acquisitions like Eli Lilly's $7.8 billion Centessa Pharma deal signal pipeline expansion into neuroscience, contrasting Pfizer's focus on oncology and cost efficiencies.
- Both stocks trade in the pharmaceuticals sector, but LLY's forward P/E ratio around 38 exceeds PFE's approximately 20, reflecting growth premium versus value positioning.
- AI technical indicators for PFE show bullish momentum with positive MACD and Aroon uptrend, while LLY displays oversold RSI suggesting potential rebound.
- Dividend yield favors PFE at about 6.5%, appealing to income-focused investors versus LLY's lower 0.7%.
Introduction
Eli Lilly (LLY) and Pfizer (PFE) represent cornerstone players in the pharmaceuticals sector, both navigating post-pandemic shifts in drug demand, pipeline innovations, and regulatory landscapes. This stock comparison analyzes their recent market performance, growth drivers, and relative positioning, aiding traders seeking momentum plays and investors eyeing long-term stability or value. With healthcare stocks under scrutiny amid economic uncertainties, understanding contrasts in momentum, valuations, and catalysts helps inform decisions on sector exposure and portfolio diversification.
LLY Overview and Recent Performance
Eli Lilly and Company (LLY), a global leader in neuroscience, cardiometabolic treatments, oncology, and immunology, derives significant revenue from GLP-1 drugs like Mounjaro for diabetes and Zepbound for obesity. In recent market activity, LLY shares have pulled back sharply, down approximately 17% YTD and 13-15% over recent weeks, trading around $887 after hitting a 52-week high near $1,134. This decline reflects broader sector pressures and competition in weight-loss therapies, partially offset by positive developments like a $7.8 billion acquisition of Centessa Pharmaceuticals to bolster sleep disorder treatments and a $2.75 billion AI-driven drug partnership with Insilico Medicine. Sentiment has softened due to high valuations (P/E around 40) and pricing challenges in markets like the UK NHS, though oversold technicals like RSI suggest potential stabilization.
PFE Overview and Recent Performance
Pfizer Inc. (PFE), a diversified pharmaceutical giant, emphasizes vaccines, oncology, rare diseases, and inflammation therapies, with a portfolio including Prevnar and ongoing obesity initiatives. Shares have shown steadier performance, up about 13% YTD and 2-4% in recent weeks, hovering near $28 after a 52-week range of $21-$28. This relative strength stems from cost-saving measures post-COVID revenue normalization, attractive dividend yield near 6.5%, and pipeline progress in areas like pancreatic cancer treatments. Investor interest has risen, with positive technical shifts including MACD histogram turning positive and Aroon uptrend, though overbought Stochastic signals caution. Forward guidance anticipates modest revenue around $60 billion, supporting defensive appeal amid volatility.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top-performing AI trading bots from hundreds available on the platform, which collectively trade thousands of tickers across diverse strategies like trend-following, momentum, and mean reversion. Only 25 bots out of over 350 total qualify for this elite section based on real-time adaptability to current market conditions, showcasing win rates often exceeding 60%, average returns in the 10-30% annual range for top performers, and risk-adjusted metrics like Sharpe ratios above 1.0. These bots vary by timeframe—from intraday scalpers to swing traders—and include healthcare-focused patterns relevant to stocks like LLY and PFE. Explore these tools to enhance your trading edge with data-driven signals tailored to volatile sectors.
Head-to-Head Comparison
Eli Lilly (LLY) and Pfizer (PFE) share pharmaceutical sector exposure but diverge in business models: LLY chases high-growth via GLP-1 dominance and M&A like Centessa, while PFE prioritizes diversified stability with oncology and vaccines post-Seagen acquisition. Growth drivers contrast sharply—LLY's revenue trajectory benefits from obesity market expansion (2025 sales ~$65B), versus PFE's ~$63B amid COVID headwinds. Recent momentum favors PFE with positive YTD gains and bullish indicators, while LLY contends with pullbacks. Risk factors include LLY's elevated valuation vulnerability to competition and PFE's patent cliffs; market sentiment leans defensive toward PFE's yield amid uncertainty.
Tickeron AI Verdict
Tickeron’s AI currently leans toward PFE due to superior recent trend consistency, positive momentum signals like MACD and Aroon uptrends, and relative stability in a choppy market. While LLY offers compelling long-term catalysts via pipeline deals, its oversold conditions and higher volatility suggest higher near-term risk. Probabilistic edge favors PFE for balanced positioning, though both warrant monitoring for sector rotations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LLY is a Hold and PFE is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LLY’s FA Score shows that 4 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).
- LLY’s FA Score: 4 green, 1 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LLY’s TA Score shows that 3 TA indicator(s) are bullish while PFE’s TA Score has 2 bullish TA indicator(s).
- LLY’s TA Score: 3 bullish, 5 bearish.
- PFE’s TA Score: 2 bullish, 5 bearish.
Price Growth
LLY (@Pharmaceuticals: Major) experienced а -1.37% price change this week, while PFE (@Pharmaceuticals: Major) price change was -5.07% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.27%. For the same industry, the average monthly price growth was +6.74%, and the average quarterly price growth was +3.04%.
Reported Earning Dates
LLY is expected to report earnings on Aug 05, 2026.
PFE is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+3.27% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| LLY | PFE | LLY / PFE | |
| Capitalization | 987B | 141B | 700% |
| EBITDA | 36.2B | 17.2B | 210% |
| Gain YTD | 3.364 | 4.101 | 82% |
| P/E Ratio | 39.15 | 19.15 | 204% |
| Revenue | 72.2B | 63.3B | 114% |
| Total Cash | 5.28B | 13.1B | 40% |
| Total Debt | 43.4B | 63.7B | 68% |
LLY | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 70 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 20 Undervalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 14 | 100 | |
SMR RATING 1..100 | 12 | 77 | |
PRICE GROWTH RATING 1..100 | 23 | 56 | |
P/E GROWTH RATING 1..100 | 86 | 42 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (5) in the Pharmaceuticals Major industry is in the same range as LLY (20). This means that PFE’s stock grew similarly to LLY’s over the last 12 months.
LLY's Profit vs Risk Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that LLY’s stock grew significantly faster than PFE’s over the last 12 months.
LLY's SMR Rating (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (77). This means that LLY’s stock grew somewhat faster than PFE’s over the last 12 months.
LLY's Price Growth Rating (23) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (56). This means that LLY’s stock grew somewhat faster than PFE’s over the last 12 months.
PFE's P/E Growth Rating (42) in the Pharmaceuticals Major industry is somewhat better than the same rating for LLY (86). This means that PFE’s stock grew somewhat faster than LLY’s over the last 12 months.
| LLY | PFE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 67% | N/A |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 56% |
| Momentum ODDS (%) | 2 days ago 66% | 2 days ago 54% |
| MACD ODDS (%) | 2 days ago 66% | 2 days ago 67% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 58% |
| TrendMonth ODDS (%) | 2 days ago 68% | 2 days ago 54% |
| Advances ODDS (%) | 16 days ago 69% | 12 days ago 56% |
| Declines ODDS (%) | 6 days ago 56% | 2 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 49% | N/A |
| Aroon ODDS (%) | 2 days ago 72% | 2 days ago 58% |
Advertisement
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.52% | ||
| BMY - PFE | 60% Loosely correlated | +1.30% | ||
| MRK - PFE | 55% Loosely correlated | +1.41% | ||
| AMGN - PFE | 53% Loosely correlated | +2.11% | ||
| NVS - PFE | 53% Loosely correlated | +1.26% | ||
| BIIB - PFE | 51% Loosely correlated | +1.59% | ||
More | ||||